SG11201909563VA - Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates - Google Patents

Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Info

Publication number
SG11201909563VA
SG11201909563VA SG11201909563VA SG11201909563VA SG 11201909563V A SG11201909563V A SG 11201909563VA SG 11201909563V A SG11201909563V A SG 11201909563VA SG 11201909563V A SG11201909563V A SG 11201909563VA
Authority
SG
Singapore
Prior art keywords
bothell
international
drive
washington
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Christopher Scott Neumann
Kathleen Olivas
Robert Lyon
Kung-Pern Wang
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201909563VA publication Critical patent/SG11201909563VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201909563V 2017-04-27 2018-04-27 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates SG11201909563VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490733P 2017-04-27 2017-04-27
US201762573987P 2017-10-18 2017-10-18
PCT/US2018/030018 WO2018201087A1 (en) 2017-04-27 2018-04-27 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Publications (1)

Publication Number Publication Date
SG11201909563VA true SG11201909563VA (en) 2019-11-28

Family

ID=62165714

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909563V SG11201909563VA (en) 2017-04-27 2018-04-27 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Country Status (14)

Country Link
US (2) US11931414B2 (enExample)
EP (1) EP3615081A1 (enExample)
JP (2) JP7425606B2 (enExample)
KR (1) KR20190141181A (enExample)
CN (1) CN110799217A (enExample)
AU (2) AU2018258687C1 (enExample)
BR (1) BR112019022445A2 (enExample)
CA (1) CA3060206A1 (enExample)
IL (1) IL269794A (enExample)
MA (1) MA51189A (enExample)
MX (2) MX2019012194A (enExample)
SG (1) SG11201909563VA (enExample)
TW (1) TW201904613A (enExample)
WO (1) WO2018201087A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI851531B (zh) 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
CA3039589A1 (en) 2016-10-18 2018-04-26 Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
CN110339181A (zh) * 2019-07-02 2019-10-18 中国药科大学 一种基于点击反应的pH响应型纳米制剂及其制法和应用
CN111454327B (zh) * 2020-04-02 2024-07-26 中国人民解放军第二军医大学 一种nampt蛋白降解靶向嵌合体及其制备方法和应用
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
WO2024052685A1 (en) 2022-09-09 2024-03-14 MyricX Pharma Limited Cytotoxic imidazo[1,2-a]pyridine compounds and their use in therapy
CN116092586B (zh) * 2023-03-10 2025-11-04 西北工业大学 一种基于生物电子等排体搜索平台的数据处理方法
WO2025162305A1 (zh) * 2024-02-01 2025-08-07 浙江养生堂天然药物研究所有限公司 含季铵盐的抗体偶联药物及其医药用途
CN119219604B (zh) * 2024-09-25 2025-11-18 大连理工大学 一种吡啶季铵盐类fk866前药、其制备方法及应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2000061559A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. N-substituted cyanoguanidine compounds
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
BR0309988A (pt) 2002-05-17 2005-02-22 Leo Pharma As Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
EP2354163A3 (en) 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
WO2009086835A1 (en) 2008-01-11 2009-07-16 Topotarget A/S Novel cyanoguanidines
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
WO2009140418A2 (en) 2008-05-14 2009-11-19 Five Prime Therapeutics, Inc. Compositions and methods for treating arthritis and/or diseases involving cartilage degeneration
WO2009156421A1 (en) 2008-06-24 2009-12-30 Topotarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
RU2011111728A (ru) 2008-08-29 2012-10-10 Топотаргет А/С (Dk) Новые производные мочевины и тиомочевины
CA2764694A1 (en) 2009-06-09 2010-12-16 Topotarget A/S Pyridinyl derivatives asinhibitors of enzyme nicotinamide phosphoribosyltransferase
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
CN103270023B (zh) 2010-09-03 2016-11-02 福马Tm有限责任公司 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
EP2611804A1 (en) 2010-09-03 2013-07-10 Forma TM, LLC. Novel compounds and compositions for the inhibition of nampt
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
MX2013005479A (es) 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
EP2648752B1 (en) 2010-12-06 2017-02-15 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
MX347459B (es) 2011-05-09 2017-04-26 Forma Tm Llc Nuevos compuestos y composiciones para la inhibición de nampt.
EP2739144A4 (en) 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc COMPOUNDS AND ITS THERAPEUTIC USE
CA2855510A1 (en) 2011-11-11 2013-05-16 Abbvie Inc. Nampt inhibitors
WO2013082150A1 (en) 2011-11-30 2013-06-06 The Curators Of The University Of Missouri Small molecule inhibitors of nicotinamide phosphoribosyltransferase (nampt)
SG11201404354UA (en) 2012-02-17 2014-10-30 Seattle Genetics Inc ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
MX2014013758A (es) 2012-05-11 2015-02-05 Abbvie Inc Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
PE20150224A1 (es) 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
AR091023A1 (es) 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN105121421B (zh) 2012-11-05 2020-10-02 辉瑞公司 司普力西欧他汀类似物
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
ITTO20130356A1 (it) 2013-05-03 2014-11-04 Uni Degli Studi Del Piemonte Orientale Ame Inibitori di nicotinamide fosforibosil transferasi, relative composizioni, prodotti ed usi
EP3055304A1 (en) 2013-10-09 2016-08-17 Eli Lilly and Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
KR102442906B1 (ko) 2013-12-19 2022-09-14 씨젠 인크. 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
CN106458934B (zh) 2014-04-18 2019-08-16 米伦纽姆医药公司 喹喔啉化合物及其用途
TW201625641A (zh) 2014-05-22 2016-07-16 健臻公司 Ｎａｍｐｔ抑制劑及方法
CA2954328A1 (en) 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
FI3900742T3 (fi) 2014-09-11 2024-08-16 Seagen Inc Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen
CN104557863B (zh) 2014-12-18 2017-03-15 中国科学院广州生物医药与健康研究院 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用
CA2974078A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
CA3039589A1 (en) 2016-10-18 2018-04-26 Seattle Genetics, Inc. Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
CA3060206A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Also Published As

Publication number Publication date
AU2018258687C1 (en) 2023-02-02
WO2018201087A1 (en) 2018-11-01
AU2022246407B2 (en) 2024-07-18
US20240293554A1 (en) 2024-09-05
EP3615081A1 (en) 2020-03-04
MA51189A (fr) 2020-03-04
JP2020517599A (ja) 2020-06-18
TW201904613A (zh) 2019-02-01
AU2022246407A1 (en) 2022-11-17
AU2018258687B2 (en) 2022-07-07
BR112019022445A2 (pt) 2020-05-12
MX2019012194A (es) 2019-12-16
JP2023119064A (ja) 2023-08-25
KR20190141181A (ko) 2019-12-23
CA3060206A1 (en) 2018-11-01
AU2018258687A1 (en) 2019-12-05
IL269794A (en) 2019-11-28
JP7425606B2 (ja) 2024-01-31
US11931414B2 (en) 2024-03-19
US20200197524A1 (en) 2020-06-25
MX2023014831A (es) 2024-01-15
CN110799217A (zh) 2020-02-14

Similar Documents

Publication Publication Date Title
SG11201909563VA (en) Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
SG11201900699QA (en) Drug conjugates with self-stabilizing linkers having improved physiochemical properties
SG11201903013SA (en) Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
SG11201900501RA (en) Cannabis composition
SG11201809627QA (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201809982RA (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201808125RA (en) Methods for solid tumor treatment
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201811559WA (en) Cancer treatment combinations
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201807526SA (en) Combination therapy using a liv1-adc and a chemotherapeutic